Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 346

1.

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.

Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS; Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators.

Arch Gen Psychiatry. 2007 Nov;64(11):1259-68.

PMID:
17984395
2.

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.

Kirbach S, Simpson K, Nietert PJ, Mintzer J.

Clin Drug Investig. 2008;28(5):291-303.

PMID:
18407715
3.

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA; CATIE-AD Study Group.

N Engl J Med. 2006 Oct 12;355(15):1525-38.

5.

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.

Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivelekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group.

Pharmacoeconomics. 2008;26(4):341-58.

PMID:
18370568
6.

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.

Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A.

Arch Gen Psychiatry. 2000 Oct;57(10):968-76.

PMID:
11015815
7.

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW.

Arch Gen Psychiatry. 2006 Oct;63(10):1079-87.

PMID:
17015810
8.

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C.

Am J Geriatr Psychiatry. 2006 Sep;14(9):767-76. Epub 2006 Aug 11. Erratum in: Am J Geriatr Psychiatry. 2006 Nov;14(11):988.

PMID:
16905684
9.

Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial.

Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, Lee E, Greenspan A.

Int J Geriatr Psychiatry. 2005 Dec;20(12):1153-7.

PMID:
16315159
10.
11.

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.

Jönsson L.

Am J Geriatr Pharmacother. 2005 Jun;3(2):77-86.

PMID:
16129384
12.

National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.

Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, Lieberman JA.

Am J Geriatr Psychiatry. 2001 Fall;9(4):346-60.

PMID:
11739062
13.

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, Markwick A, Lloyd H; CUtLASS team.

Br J Psychiatry. 2007 Jul;191:14-22.

14.

Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.

Kurlan R, Cummings J, Raman R, Thal L; Alzheimer's Disease Cooperative Study Group.

Neurology. 2007 Apr 24;68(17):1356-63.

PMID:
17452579
15.

Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Rosenheck RA, Hsiao JK, Lieberman JA, Schneider LS; CATIE-AD Study Group.

Am J Psychiatry. 2008 Jul;165(7):844-54. doi: 10.1176/appi.ajp.2008.07111779. Epub 2008 Jun 2.

16.

Cost-effectiveness of improving primary care treatment of late-life depression.

Katon WJ, Schoenbaum M, Fan MY, Callahan CM, Williams J Jr, Hunkeler E, Harpole L, Zhou XH, Langston C, Unützer J.

Arch Gen Psychiatry. 2005 Dec;62(12):1313-20.

PMID:
16330719
17.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

19.

The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.

Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H.

Int J Geriatr Psychiatry. 2007 May;22(5):475-84.

PMID:
17471598
20.

A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.

Beard SM, Maciver F, Clouth J, Rüther E.

Eur J Health Econ. 2006 Sep;7(3):165-72.

PMID:
16896764
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk